Healthcare / Medical DevicesKOSDAQ
$10420.00
-180.00 (-1.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 22%
FCF escenarios
weak_data · normalized FCF $12.4B · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$223.4B
P/E
9.6x
↓EV/EBITDA
5.9x
↓ROE
10.2%
↑Gross Margin
59.2%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.1%
FCF CAGR
—
FCF margin
-7.4%
FCF / Net income
-0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $162.09B · net income $23.65B · FCF $-11.94B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $162.09B | $162.09B | $138.16B | $134.22B | $118.08B |
| Net Income | $23.65B | $23.65B | $27.26B | $25.95B | $24.15B |
| EBITDA | $38.25B | $38.25B | $41.20B | $40.15B | $34.64B |
| EPS | 1091.00 | 1091.00 | 1242.00 | 1181.00 | 1080.00 |
| Gross Margin | 59.2% | 59.2% | 59.2% | 60.3% | 60.0% |
| Operating Margin | 17.9% | 17.9% | 18.9% | 21.2% | 20.9% |
| Net Margin | 14.6% | 14.6% | 19.7% | 19.3% | 20.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.05 | 0.06 | 0.05 |
| Current Ratio | 5.55 | 5.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-11.94B | $-11.94B | $12.41B | $28.67B | $6.16B |
| Returns | |||||
| ROE | 10.2% | 10.2% | 13.0% | 13.9% | 14.8% |
| Valuation | |||||
| P/E | 9.55 | 9.55 | 13.69 | 15.98 | 9.86 |
| EV/EBITDA | 5.86 | 5.86 | 8.16 | 9.53 | 6.37 |
| P/B | 0.98 | 0.98 | 1.77 | 2.23 | 1.46 |
| Growth & Yield | |||||
| Revenue Growth | 17.3% | 17.3% | 2.9% | 13.7% | — |
| EPS Growth | -12.2% | -12.2% | 5.2% | 9.4% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-5.4%
EPS terminal req.
$924.60
Spread vs growth
-6.8%
5Y implied EPS CAGR
0.5%
EPS terminal req.
$1118.77
Spread vs growth
-12.7%
10Y implied EPS CAGR
5.1%
EPS terminal req.
$1801.79
Spread vs growth
-17.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.1%
Start / end P/E
12.8x → 9.6x
EPS bridge
1242.00 → 1091.00
Residual
+3.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.